Previous Close | 319.78 |
Open | 317.28 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 319.85 - 322.18 |
52 Week Range | 287.90 - 389.37 |
Volume | |
Avg. Volume | 11,295 |
Market Cap | N/A |
Beta (5Y Monthly) | 1.42 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Transcendia Holdings, Inc. ("Transcendia" or the "Company"), a leader in manufacturing and converting custom engineered films, today announced it has entered into an agreement for a recapitalization transaction that will strengthen the Company's financial position and create a sustainable, long-term capital structure for the next phase of growth. The transaction will provide Transcendia with $114 million in new capital, eliminate more than $200 million of the Company's debt and further strengthe
Ms. Salka brings more than 30 years of healthcare leadership and staffing expertise, including strong C-suite, financial and ESG expertise to advance the company’s Patients-first focus and growth initiativesDURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Susan R. Salka, retired Chief Executive Officer and President
DirectBooks, a global leader in primary markets communications, announced today that Santander, Ramirez & Co. and Mischler Financial Group have joined the platform. The recent additions increase the number of underwriters participating on DirectBooks to 34 worldwide.